Disclosure: I am the author of Navigating Cancer Between Hope and Hype and receive royalties from its sale. This article also contains Amazon Associates affiliate links; if you purchase through one of those links, I may earn a small commission at no additional cost to you.

After a cancer diagnosis, information is rarely the scarce resource.

There are treatment pages, research papers, survivor stories, podcasts, social-media protocols, clinical trials, supplement claims, repurposed-drug discussions, expert opinions, second opinions, and people who sound absolutely certain that they know what you should do next.

The harder problem is deciding what deserves confidence, what deserves curiosity, what deserves caution, and what actually applies to the person sitting in front of all of it.

That is the problem I eventually came to think of as navigation. It is also the reason I spent more than two years researching and writing Navigating Cancer Between Hope and Hype.

Cancer Does Not Create an Information Vacuum

It creates an information flood.

In the United States, cancer remains extraordinarily common. The National Cancer Institute’s SEER program currently estimates that about 39 percent of people will be diagnosed with cancer at some point during their lifetime. The American Cancer Society estimated more than two million new U.S. cancer cases in 2025.

At the same time, the picture is not as simple as saying cancer is uniformly increasing everywhere. A 2025 National Institutes of Health analysis found rising incidence for 14 of 33 cancer types in at least one younger age group, including notable absolute increases in female breast, colorectal, kidney, uterine, and pancreatic cancers. But most of those cancers did not show increasing mortality among younger people, and the researchers cautioned that the causes are likely cancer-specific and may include changing risk factors, screening, detection, and diagnostic practices.

Those distinctions matter. They are exactly the kind of distinctions that disappear when a frightening statistic is stripped of context and turned into a headline.

The Second Problem Arrives After the Diagnosis

The medical diagnosis is real. But another problem often follows it: the patient suddenly has to make consequential decisions while frightened, exhausted, uncertain, and surrounded by claims that do not carry equal evidentiary weight.

I have written separately about this as the second diagnosis — cancer and information overload. I do not want to repeat that entire argument here. The important point is that collecting more information does not automatically produce a better decision.

What is missing is a way to orient yourself inside the information.

Why I Wrote the Book

I did not set out to write another book telling people with cancer which treatment to choose.

I wanted to build something more durable: a way to think when the answer is not obvious, when qualified experts disagree, when an unconventional claim has some evidence but not enough evidence, when a conventional recommendation has tradeoffs, and when the person making the decision has values and circumstances that cannot be reduced to a treatment guideline.

That required confronting two opposite mistakes.

One is blind trust: assuming that an institution, credential, guideline, study, or approved treatment should end the evaluation simply because it carries authority.

The other is reflexive distrust: assuming that mainstream medicine is compromised while an outsider, influencer, testimonial, inexpensive repurposed drug, or “natural” protocol deserves confidence precisely because it sits outside the system.

Neither posture is navigation. Both replace evaluation with allegiance.

The Outcome Belongs to Biology. The Process Belongs to the Patient.

This became one of the most important distinctions in the book.

A person can research carefully, ask excellent questions, communicate honestly with the medical team, weigh evidence appropriately, understand risks, clarify values, and make a thoughtful decision — and still experience an outcome nobody wanted.

Good navigation does not create control where control does not exist. It improves the quality of the process where agency does exist.

That matters because cancer culture can quietly create a responsibility trap: if the treatment fails, the patient wonders whether they chose badly, researched too little, failed to find the hidden answer, ate the wrong thing, trusted the wrong doctor, or did not fight hard enough.

The framework I built rejects that burden. The goal is not to guarantee the outcome. It is to make the best available decision with the evidence, circumstances, risks, values, and time available — and to know what would cause you to reassess it.

From an Evidence Ladder to a Decision Compass

The book develops a series of tools rather than one formula.

The NVA Evidence Ladder asks where a claim honestly belongs in the hierarchy of evidence. A laboratory finding is not a randomized human trial. A case report is not a systematic review. But lower-level evidence is not worthless simply because it is early. The point is to contextualize evidence rather than either worship it or dismiss it.

The Incentive Audit asks a different question: who is producing, interpreting, promoting, or profiting from the claim, and what are they optimizing for? Pharmaceutical companies have incentives. Academic researchers have incentives. Hospitals have incentives. Supplement companies have incentives. Influencers and alternative-health communities have incentives. Recognizing that does not mean nobody can be trusted. It means trust should be calibrated rather than automatic.

Those tools eventually feed into the NVA Decision Compass, which brings together evidence, incentives, risk and reward, the cost of being wrong, time and urgency, expertise, personal values and goals, and reassessment. The Compass exists because certainty is often unavailable. A usable decision process cannot depend on achieving certainty first.

This is also why a clinical trial and an established treatment can both be rational options in different circumstances. The question is not merely which option sounds more promising. It is what the evidence actually supports, what remains unknown, what the risks and opportunity costs are, what matters to this particular patient, and what new information would change the decision.

When the Evidence Moves, the Assessment Has to Move

A framework for navigating evidence has to be capable of changing its assessment when the evidence changes.

Repurposed cancer drugs provide a useful example. In the book, I distinguish fenbendazole, mebendazole, and ivermectin rather than treating them as interchangeable. Mebendazole already had a legitimate early human oncology research pathway. Fenbendazole remained primarily preclinical, with case reports and ongoing research but without completed randomized human efficacy trials. Ivermectin had substantial preclinical interest along with limited observational and early human investigation, but no completed Phase III randomized evidence demonstrating a cancer benefit. I apply this framework in more detail in How to Evaluate a ‘Repurposed Drug’ Cancer Claim.

Since the manuscript was completed, formal investigation has continued. A newer University of Florida Phase II study, ICONIC, is examining ivermectin in combination with immune-checkpoint inhibition, while an earlier Phase I/II study has been investigating ivermectin with immunotherapy in metastatic triple-negative breast cancer. The newer trial is especially interesting because its rationale acknowledges the widespread public awareness and off-label interest surrounding ivermectin.

That development does not establish ivermectin as an effective cancer treatment. A trial beginning or progressing is evidence that a question is being formally investigated; it is not the answer to the question.

But the opposite mistake would be refusing to update our assessment because a claim once lived mostly in laboratory research, online communities, or off-label use. If stronger human evidence emerges, its position on the Evidence Ladder should change. If well-designed trials fail, confidence should change in the other direction.

That is not inconsistency. That is what an evidence-based framework is supposed to do.

For practical examples, see How to Evaluate a ‘Repurposed Drug’ Cancer Claim and What Clinical Trial Phases Actually Tell You (And What They Don’t).

What I Ultimately Tried to Build

Navigating Cancer Between Hope and Hype is not an argument for conventional medicine over alternative medicine, or alternative medicine over conventional medicine.

It is an argument for better navigation.

That means understanding what evidence can and cannot tell you. It means recognizing incentives without turning skepticism into cynicism. It means separating symptom relief from claims of tumor control or cure. It means understanding clinical trials without mistaking experimental access for proven benefit. It means protecting hope without attaching hope to a single protocol. And it means making values-aligned decisions under uncertainty without blaming yourself for biology you cannot control.

The complete framework took 30 chapters and 487 pages because cancer navigation cannot honestly be reduced to a list of “good” and “bad” treatments. The landscape changes. Evidence changes. Individual circumstances change. The navigation process has to be strong enough to move with them.

If You’re Trying to Find Your Next Step

You do not need to solve the entire cancer landscape tonight.

You need a reliable way to identify the next question, evaluate the next claim, understand the next decision, and recognize what would cause you to reconsider it.

Start With the Decision Framework

If you’re trying to evaluate a cancer claim or treatment option without getting lost in the noise, start with the free NVA Decision Framework Checklist. It gives you a practical way to work through evidence, risk, uncertainty, and the questions worth asking next.

Get the Free Decision Framework

Want the broader introduction first? Read the free Navigating Cancer overview. For the complete framework, visit the NVA book page for Navigating Cancer Between Hope and Hype, with paperback and Kindle options available there.

Sources and Further Reading

This article is educational and is not medical advice. Cancer treatment decisions should be made with a qualified oncology team familiar with the individual’s diagnosis, treatment history, medications, goals, and clinical circumstances.

Why the Cancer Crisis Isn’t Information — It’s Navigation